The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 301–400 of 1,002
Zhou, Z., Mai, Y., Zhang, G., Wang, Y., Sun, P., Jing, Z., Li, Z., Xu, Y., Han, B. R., & Liu, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217079 · Cited by 45
Xia, Z., Jin, Q., Long, Z., He, Y., Liu, F., Sun, C., Liao, J., Wang, C., Wang, C., Zheng, J., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01258-8 · Cited by 43
Zhang, C., Fang, L., Wang, X., Yuan, S., Li, W., Tian, W., Chen, J., Zhang, Q., Zhang, Y., Zhang, Q., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.018 · Cited by 41
Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges
Rafii, S., Tashkandi, E. M., Bukhari, N., & Al-Shamsi, H. O. (2022) · Cancers · doi:10.3390/cancers14040947 · Cited by 45
O-GlcNAcylation and Its Role in Cancer-Associated Inflammation
Ouyang, M., Yu, C., Deng, X., Zhang, Y., Zhang, X., & Duan, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861559 · Cited by 43
Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
Miao, L., Zhang, J., Huang, B., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832765 · Cited by 45
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42
Advancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 44
Antonucci, L., Canciani, G., Mastronuzzi, A., Carai, A., Baldo, G. D., & Bufalo, F. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867154 · Cited by 39
Lin, J., Li, D., Li, C., Zhuang, Z., Chu, C., Ostrikov, K., Thompson, E. W., Liu, G., & Wang, P. (2023) · Nanoscale · doi:10.1039/d3nr01735d · Cited by 43
Emerging Immunotherapy Approaches for Treating Prostate Cancer
Meng, L., Yang, Y., Mortazavi, A., & Zhang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814347 · Cited by 41
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C. P., Singh, A. K., Bhat, A. A., Macha, M. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11111721 · Cited by 40
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
Cutri‐French, C., Nasioudis, D., George, E. M., & Tanyi, J. L. (2024) · Diagnostics · doi:10.3390/diagnostics14080819 · Cited by 40
Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
Moradi, V., Khodabandehloo, E., Alidadi, M., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388475 · Cited by 42
Erler, P., Kurćon, T., Cho, H., Skinner, J. N., Dixon, C., Grudman, S., Rozlan, S., Dessez, E., Mumford, B., Jo, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn9857 · Cited by 41
Albelo-Martínez, M., & Rizvi, S. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00601 · Cited by 46
Gut Microbiota Modulation through Akkermansia spp . Supplementation Increases CAR T-cell Potency
Marcos-Kovandzic, L., Avagliano, M., Khelil, M. B., Srikanthan, J., Abdallah, R., Petrocelli, V., Rengassamy, J., Alfaro, A., Bied, M., Fidelle, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1230 · Cited by 42
Converging Mechanisms of Epileptogenesis and Their Insight in Glioblastoma
Hills, K., Kostarelos, K., & Wykes, R. C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.903115 · Cited by 44
André, A., Moutinho, I., Dias, J., & Aires‐da‐Silva, F. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.962124 · Cited by 47
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Li, Y., Rezvani, K., & Rafei, H. (2023) · Immunological Reviews · doi:10.1111/imr.13255 · Cited by 41
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
Lipid anchor-mediated NK cell surface engineering for enhanced cancer immunotherapy
Kim, S., Li, S., Gajendiran, M., Jangid, A. K., Lee, D., Jung, H.-S., & Kim, K. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145211 · Cited by 39
Najafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 39
Hou, F., Guo, Z., Ho, M. T., Hui, Y., & Zhao, C. (2024) · ACS Nano · doi:10.1021/acsnano.3c10180 · Cited by 40
Salnikov, M. Y., MacNeil, K. M., & Mymryk, J. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358511 · Cited by 43
Huang, Y., Qin, Y., He, Y., Qiu, D., Zheng, Y., Wei, J., Zhang, L., Yang, D., & Li, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101082 · Cited by 40
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
Montoya, M., Gallus, M., Phyu, S. M., Haegelin, J., de Groot, J., & Okada, H. (2024) · Cells · doi:10.3390/cells13090726 · Cited by 43
Li, X., Zhao, L., Li, W., Gao, P., & Zhang, N. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00275-6 · Cited by 39
Immunomodulatory metal-based biomaterials for cancer immunotherapy
Yuan, K., Zhang, C., Pan, X., Hu, B., Zhang, J., & Yang, G. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.008 · Cited by 40
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
Zhang, B., Wu, J., Jiang, H., & Zhou, M. (2025) · Cells · doi:10.3390/cells14050320 · Cited by 39
The biological role and immunotherapy of gangliosides and GD3 synthase in cancers
Cao, S., Hu, X., Ren, S., Wang, Y., Shao, Y., Wu, K., Yang, Z. F., Yang, W., He, G., & Li, X. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1076862 · Cited by 40
Single-cell mapping of combinatorial target antigens for CAR switches using logic gates
Kwon, J., Kang, J., Jo, A., Seo, K., An, D., Baykan, M. Y., Lee, J. H., Kim, N., Eum, H. H., Hwang, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01686-y · Cited by 38
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Saetzler, V., Riët, T., Schienke, A., Henschel, P., Freitag, K., Haake, A. F. H., Heppner, F. L., Buitrago‐Molina, L. E., Noyan, F., Jaeckel, E., et al. (2023) · Cells · doi:10.3390/cells12162115 · Cited by 39
Beyond youth: Understanding CAR T cell fitness in the context of immunological aging
Noll, J. H., Levine, B. L., June, C. H., & Fraietta, J. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101840 · Cited by 41
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 45
Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia
Bartoszewska, E., Tota, M., Kisielewska, M., Skowron, I., Sebastianka, K., Stefaniak, O., Molik, K., Rubin, J., Kraska, K., & Choromańska, A. (2024) · Cells · doi:10.3390/cells13181596 · Cited by 41
Ramadan, E., Ismeal, A. A. A., & Naguib, Y. W. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14111092 · Cited by 42
Nanoparticles hijack calvarial immune cells for CNS drug delivery and stroke therapy
Gao, X., Liu, X., Wang, N., Cui, C., Liu, W., Yang, M., Li, Q., Ou, Y., Ning, A., Wei, X., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.008 · Cited by 40
Becker, M. W., Peters, L. D., Myint, T. S., Smurlick, D., Powell, A., Brusko, T. M., & Phelps, E. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1082 · Cited by 37
Challenges and solutions for therapeutic TCR ‐based agents
Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S. A., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13233 · Cited by 37
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system
Calvillo‐Rodríguez, K. M., Lorenzo-Anota, H. Y., Rodrı́guez-Padilla, C., Martínez‐Torres, A. C., & Scott‐Algara, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294434 · Cited by 37
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Zhu, C., Wu, Q., Sheng, T., Shi, J., Shen, X., Yu, J., Du, Y., Sun, J., Liang, T., He, K., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.002 · Cited by 39
Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils
Liang, Y., Xu, Q., & Gao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291619 · Cited by 39
Cancer Vaccines in the Immunotherapy Era: Promise and Potential
Verma, C., Pawar, V. A., Srivastava, S., Tyagi, A., Kaushik, G., Shukla, S. K., & Kumar, V. (2023) · Vaccines · doi:10.3390/vaccines11121783 · Cited by 40
Hansen, D. K., Liu, Y.-H., Ranjan, S., Bhandari, H., Potluri, R. C., McFarland, L., Braganca, K. C. D., & Huo, S. (2023) · Cancers · doi:10.3390/cancers15245746 · Cited by 37
Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy
Maia, A., Tarannum, M., & Romee, R. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad087 · Cited by 37
Mechanical forces amplify TCR mechanotransduction in T cell activation and function
Jeffreys, N. C., Brockman, J. M., Zhai, Y., Ingber, D. E., & Mooney, D. J. (2024) · Applied Physics Reviews · doi:10.1063/5.0166848 · Cited by 41
Kong, J. C., Sa’ad, M. A., Vijayan, H. M., Ravichandran, M., Balakrishnan, V., Tham, S. K., & Tye, G. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384039 · Cited by 37
Immunotherapy for colorectal cancer
Yu, B., Kang, J., Lei, H., Li, Z., Yang, H. C., & Zhang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433315 · Cited by 39
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 40
Tracing the development of CAR-T cell design: from concept to next-generation platforms
Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 49
Younas, A., Wang, S., Asad, M., Mamun, A. A., Majeed, S., Sharif, A., Zhou, Q., Liu, Y., Geng, P., Shao, C., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102660 · Cited by 42
Moreno, C. M., Haynie, C., Cheever, A., & Weber, K. S. (2022) · Biomedicines · doi:10.3390/biomedicines10071493 · Cited by 39
Marella, M., Yao, X., Carreira, V., Bustamante, M. F., Clark, H. B., Jackson, C. C., Zudaire, E., Schecter, J. M., Glover, T. D., Shenton, J. M., et al. (2022) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554221079579 · Cited by 36
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 37
RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells
Bouquet, L., Bôle‐Richard, E., Warda, W., Rocha, M. N. D., Trad, R., Nicod, C., Haderbache, R., Genin, D., Ferrand, C., & Deschamps, M. (2023) · Gene Therapy · doi:10.1038/s41434-023-00404-2 · Cited by 38
Closset, L., Gultekin, O., Salehi, S., Sarhan, D., Lehti, K., & Gonzalez‐Molina, J. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.07.003 · Cited by 36
Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection
Rosado‐Sánchez, I., Haque, M., Salim, K., Speck, M., Fung, V. C. W., Boardman, D. A., Mojibian, M., Raimondi, G., & Levings, M. K. (2023) · JCI Insight · doi:10.1172/jci.insight.167215 · Cited by 37
Liu, Q., Hu, Y., Zheng, P., Yang, Y., Fu, Y., Yang, Y., Duan, B., Wang, M., Li, D., Li, W., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02031-w · Cited by 36
Mohammadi, V., Maleki, A. J., Nazari, M., Siahmansouri, A., Moradi, A., Elahi, R., & Esmaeilzadeh, A. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10668-1 · Cited by 38
Kachanov, A., Kostyusheva, A., Brezgin, S., Karandashov, I., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 44
CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects
Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38
Mehta, A., Popplewell, L. L., Collins, G. P., Smith, S. M., Flinn, I. W., Bartlett, N. L., Ghosh, N., Hacohen-Kleiman, G., Huo, Y., Su-Feher, L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013277 · Cited by 36
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 47
The role of neoantigens in tumor immunotherapy
Shang, S., Zhao, Y., Qian, K., Qin, Y., Zhang, X., Li, T., Shan, L., Wei, M., Xi, J., & Tang, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113118 · Cited by 37
Reprogramming the tumor microenvironment with biotechnology
Kim, M., Lee, N. K., Wang, C. J., Lim, J., Byun, M. J., Kim, T. P., Park, W., Park, D.-H., Kim, S.-N., & Park, C. G. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00343-4 · Cited by 37
Non-Mammalian Eukaryotic Expression Systems Yeast and Fungi in the Production of Biologics
Garvey, M. (2022) · Journal of Fungi · doi:10.3390/jof8111179 · Cited by 28
Challenges and future of HER2-positive gastric cancer therapy
Ma, C., Wang, X., Guo, J., Yang, B., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1080990 · Cited by 40
Bücklein, V., Perez, A. P., Rejeski, K., Iacoboni, G., Jurinović, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000907 · Cited by 36
Safety risks and ethical governance of biomedical applications of synthetic biology
Ou, Y., & Guo, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1292029 · Cited by 39
Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02838-3 · Cited by 36
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges
Harrer, D. C., Li, S., Kaljanac, M., Barden, M., Pan, H., & Abken, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1321596 · Cited by 34
Yiğit, M., Basoglu, O. F., & Unutmaz, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369236 · Cited by 34
Kong, D., Kwon, D., Moon, B., Kim, D.-H., Kim, M.-J., Choi, J., & Kang, K.-S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116436 · Cited by 35
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 41
Wu, Z., Wang, H., Zheng, Z., Lin, Y., Bian, L., Geng, H., Huang, X., Zhu, J., Jing, H., Zhang, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06276-x · Cited by 35
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 43
Gene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 43
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
Jafari, M., Kadkhodazadeh, M., Shapourabadi, M. B., Goradel, N. H., Shokrgozar, M. A., Arashkia, A., Abdoli, S., & Sharifzadeh, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012806 · Cited by 37
Personalized hematopoietic stem cell transplantation for inborn errors of immunity
Slatter, M. A., & Lum, S. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162605 · Cited by 38
Montalvo, M. J., Bandey, I. N., Rezvan, A., Wu, K.-L., Saeedi, A., Kulkarni, R. S., Li, Y., An, X., Sefat, K. M. S. R., & Varadarajan, N. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06461-8 · Cited by 42
Novel and potential future therapeutic options in systemic autoimmune diseases
Balogh, L., Oláh, K., Sánta, S., Majerhoffer, N., & Németh, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1249500 · Cited by 36
Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy
Huang, S., Xu, J., Baran, N., & Ma, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117753 · Cited by 34
The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies
Khan, T. H., Muhammad, N., Tarique, M., Usmani, D., Naz, H., & Sarode, A. Y. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-024-00055-4 · Cited by 33
Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells
Hu, D., Yang, R., Wang, G., Li, H., Fan, X., & Liang, G. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s445101 · Cited by 34
Liu, C., Gao, J., Cheng, Y., Zhang, S., & Fu, C. (2024) · Regenerative Biomaterials · doi:10.1093/rb/rbae135 · Cited by 33
Lam, P. Y., Omer, N., Wong, J., Tu, C., Alim, L., Rossi, G. R., Victorova, M., Tompkins, H., Lin, C., Mehdi, A. M., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70140 · Cited by 35
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy
Justiz-Vaillant, A. A., Pandit, B. R., Unakal, C. G., Vuma, S., & Akpaka, P. E. (2025) · Antibodies · doi:10.3390/antib14020035 · Cited by 37
Pan, X., Wang, Z., Tan, M., Fu, Z., Nie, G., & Wang, H. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01909-0 · Cited by 33
Wang, H., Zhan, H., Pan, B., Zeng, L., Chen, Z., Liu, S., Zhang, Q., Hong, X., Lu, J., Lin, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501565 · Cited by 33
von Locquenghien, M., Zwicky, P., Xie, K., Jaitin, D. A., Sheban, F., Yalin, A., Uhlitz, F., Gur, C., Sharet-Eshed, R., David, E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.030 · Cited by 41
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38
Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M. Y., Lossos, I. S., Geethakumari, P. R., Lam, S., Calvo, R., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18368 · Cited by 33
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 36
Recent Developments in Nanoparticle‐Based Photo‐Immunotherapy for Cancer Treatment
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2023) · Small Methods · doi:10.1002/smtd.202300252 · Cited by 34
Tumor neoantigens: Novel strategies for application of cancer immunotherapy
Guan, H., Wu, Y., Li, L., Yang, Y., Qiu, S., Zhao, Z., Chu, X., He, J., Chen, Z., ZHANG, Y., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029924 · Cited by 34
Ukrainskaya, V. M., Musatova, O. E., Volkov, D. V., Osipova, D. S., Pershin, D., Moysenovich, A. M., Evtushenko, E. G., Kulakovskaya, E. A., Maksimov, E. G., Zhang, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27604-5 · Cited by 32
Zinzi, A., Gaio, M., Liguori, V., Cagnotta, C., Paolino, D., Paolisso, G., Castaldo, G., Nicoletti, G. F., Rossi, F., Capuano, A., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106742 · Cited by 33
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
